Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes
Abstract
To investigate the effects of sulfonylurea receptor 1 (SUR1) exon 33 (TCC
→
GCC, S1369A) polymorphism on responsiveness to gliclazide. About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks. SUR1 genotypes were tested by Taqman-PCR. After gliclazide treatment, there was association between T/G polymorphism and decrease of HbA1c. G carriers were more sensitive to gliclazide and the decrease of HbA1c was more significant than TT genotype (TT, 0.76%
±
1.70%; TG
+
GG, 1.60%
±
1.39%, P
=
0.044). The polymorphism of SUR1S1369A was associated with the therapeutic efficacy of gliclazide.
Keywords: Type 2 diabetes, Polymorphism, Gliclazide
To access this article, please choose from the options below
PII: S0168-8227(06)00492-X
doi:10.1016/j.diabres.2006.10.021
© 2006 Elsevier Ireland Ltd. All rights reserved.
